NeoGenomics Launches RaDaR ST, Expanding MRD Testing Across Multiple Solid Tumors (businesswire.com)

• RaDaR ST detects MRD in multiple solid tumor types
• Tumor-informed ctDNA-based liquid biopsy
• Performed in NeoGenomics' CLIA/CAP-accredited US lab

"NeoGenomics launched RaDaR ST, a molecular residual disease (MRD) test for multiple solid tumor types. The tumor-informed liquid biopsy detects ctDNA to identify recurrence. Validated clinically, it expands NeoGenomics' precision oncology portfolio and targets the growing MRD testing market."